Myriad Genetics Inc (MYGN)
Receivables turnover
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 837,600 | 823,600 | 802,200 | 774,200 | 753,200 | 734,400 | 698,900 | 694,700 | 678,400 | 661,400 | 672,300 | 682,400 | 690,600 | 684,400 | 662,300 | 566,100 | 557,000 | 597,500 | 638,600 | 760,800 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $837,600K ÷ $—K
= —
The receivables turnover ratio for Myriad Genetics Inc is not provided in the data for the periods stated. This ratio is an important metric that measures how efficiently a company is able to collect payments from its customers on credit sales. By having this ratio, we can assess the effectiveness of the company's accounts receivable management.
Given the absence of receivables turnover data in the provided information, a detailed analysis of this ratio's trend, comparison to industry benchmarks, and assessment of any underlying factors influencing collection efficiency cannot be performed. It is recommended to obtain the actual receivables turnover values for the respective periods in order to evaluate Myriad Genetics Inc's performance in managing its accounts receivable effectively.
Peer comparison
Dec 31, 2024